Neurocrine Biosciences Inc NBIX
10 trading plans running, 26 Form 144 notices for $88.5M
10-Q, 10-K and Form 144What NBIX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Mar 5, 2026 to May 18, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in |
|---|---|---|---|
| William Rastetter Director |
Adopted 10b5-1 plan | Sep 3, 2026 | 10-Q Nov 2, 2026 |
| Julie Cooke Chief Human Resource Officer |
Adopted 10b5-1 plan | Aug 31, 2026 | 10-Q Nov 2, 2026 |
| Richard Pops Director |
Adopted 10b5-1 plan | Aug 27, 2026 | 10-Q Nov 2, 2026 |
| Gary Lyons Director |
Adopted 10b5-1 plan | Aug 18, 2026 | 10-Q Nov 2, 2026 |
| David Boyer Chief Corporate Affairs Officer |
Adopted 10b5-1 plan | Aug 11, 2026 | 10-Q Nov 2, 2026 |
| Sanjay Keswani Chief Medical Officer (through Sep. 25, 2026) |
Adopted 10b5-1 plan | Aug 7, 2026 | 10-Q Nov 2, 2026 |
| Eric Benevich Chief Commercial Officer |
Adopted 10b5-1 plan | Jun 9, 2026 | 10-Q Jul 31, 2026 |
| George Morrow Director |
Adopted 10b5-1 plan | May 26, 2026 | 10-Q Jul 31, 2026 |
| Matthew Abernethy Chief Financial Officer |
Adopted 10b5-1 plan | May 22, 2026 | 10-Q Jul 31, 2026 |
| Stephen Sherwin Director |
Adopted 10b5-1 plan | Mar 5, 2026 | 10-Q May 5, 2026 |
| Richard Pops Director |
Adopted 10b5-1 plan | Feb 13, 2026 | 10-Q May 5, 2026 |
| Kevin Gorman, Ph.D. Director |
Ended 10b5-1 plan | Feb 4, 2026 | 10-Q May 5, 2025 |
| Darin Lippoldt Chief Legal Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| David Boyer Chief Corporate Affairs Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Eric Benevich Chief Commercial Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Ingrid Delaet Chief Regulatory Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Jude Onyia Chief Scientific Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Julie Cooke Chief Human Resources Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Kevin Gorman Director |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Kyle Gano Chief Executive Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Matthew Abernethy Chief Financial Officer |
Ended 10b5-1 plan | Jan 20, 2026 | 10-Q May 5, 2026 |
| Leslie Norwalk Director |
Adopted 10b5-1 plan | Sep 12, 2025 | 10-Q Oct 28, 2025 |
| Gary Lyons Director |
Adopted 10b5-1 plan | Sep 3, 2025 | 10-Q Oct 28, 2025 |
| Eric Benevich Chief Commercial Officer |
Adopted 10b5-1 plan | Aug 28, 2025 | 10-Q Oct 28, 2025 |
| George Morrow Director |
Adopted 10b5-1 plan | Aug 26, 2025 | 10-Q Oct 28, 2025 |
| William Rastetter Director |
Adopted 10b5-1 plan | Aug 6, 2025 | 10-Q Oct 28, 2025 |
| Darin Lippoldt Chief Legal Officer |
Adopted 10b5-1 plan | Jun 9, 2025 | 10-Q Jul 30, 2025 |
| Matthew Abernethy Chief Financial Officer |
Adopted 10b5-1 plan | May 23, 2025 | 10-Q Jul 30, 2025 |
| Kyle Gano Chief Executive Officer |
Adopted 10b5-1 plan | May 20, 2025 | 10-Q Jul 30, 2025 |
| David W. Boyer Chief Corporate Affairs Officer |
Adopted 10b5-1 plan | Dec 11, 2024 | 10-K Feb 10, 2025 |
| Jude Onyia, Ph.D. Chief Scientific Officer |
Ended 10b5-1 plan | Nov 18, 2024 | 10-K Feb 10, 2025 |
| Stephen A. Sherwin, M.D. Director |
Adopted 10b5-1 plan | Nov 7, 2024 | 10-K Feb 10, 2025 |
| David Boyer Chief Corporate Affairs Officer |
Adopted 10b5-1 plan | Jun 14, 2024 | 10-Q Aug 1, 2024 |
| Kevin Gorman, Ph.D. Chief Executive Officer |
Adopted 10b5-1 plan | Jun 14, 2024 | 10-Q Aug 1, 2024 |
| William Rastetter, Ph.D. Director |
Adopted 10b5-1 plan | Jun 14, 2024 | 10-Q Aug 1, 2024 |
| Julie S. Cooke Chief Human Resources Officer |
Adopted 10b5-1 plan | Mar 17, 2024 | 10-Q May 1, 2024 |
| Kyle W. Gano Chief Business Development & Strategy Officer |
Adopted 10b5-1 plan | Mar 15, 2024 | 10-Q May 1, 2024 |
| Gary A. Lyons Director |
Adopted 10b5-1 plan | Feb 13, 2024 | 10-Q May 1, 2024 |
| Matthew C. Abernethy Chief Financial Officer |
Adopted 10b5-1 plan | Feb 13, 2024 | 10-Q May 1, 2024 |
| George Morrow (Director) |
Adopted 10b5-1 plan | Dec 14, 2023 | 10-K Feb 9, 2024 |
| Eric Benevich (Chief Commercial Officer) |
Ended 10b5-1 plan | Nov 30, 2023 | 10-K Feb 9, 2024 |
| Ingrid Delaet (Chief Regulatory Officer) |
Adopted 10b5-1 plan | Nov 29, 2023 | 10-K Feb 9, 2024 |
| Leslie Norwalk (Director) |
Adopted 10b5-1 plan | Nov 28, 2023 | 10-K Feb 9, 2024 |
| Shalini Sharp (Director) |
Adopted 10b5-1 plan | Nov 27, 2023 | 10-K Feb 9, 2024 |
| Richard Pops (Director) |
Adopted 10b5-1 plan | Nov 21, 2023 | 10-K Feb 9, 2024 |
| Darin M. Lippoldt (Chief Legal Officer) |
Adopted 10b5-1 plan | Aug 24, 2023 | 10-Q Oct 31, 2023 |
| Kevin C. Gorman (Chief Executive Officer) |
Adopted 10b5-1 plan | Aug 22, 2023 | 10-Q Oct 31, 2023 |
| David W. Boyer (Chief Corporate Affairs Officer) |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 1, 2023 |
| William H. Rastetter (Chair of the Board of Directors) |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 1, 2023 |
Show the other 41 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 3, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 10, 2026 | SANJAY KESWANI Former Affiliate |
53,614 | $9.0M |
| Nov 2, 2026 | GEORGE MORROW Director |
14,700 | $2.1M |
| Oct 30, 2026 | GEORGE MORROW Director |
300 | $44K |
| Sep 14, 2026 | MATTHEW C ABERNETHY Officer |
2,311 | $361K |
| Sep 14, 2026 | DAVID WARREN BOYER Officer |
4,714 | $736K |
| Sep 9, 2026 | ERIC BENEVICH Officer |
2,154 | $334K |
| Jul 10, 2026 | INGRID DELAET Officer |
4,367 | $788K |
| Jul 9, 2026 | DARIN LIPPOLDT Officer |
10,000 | $1.8M |
| Jul 7, 2026 | INGRID DELAET Officer |
14,571 | $2.5M |
| Jun 29, 2026 | DARIN LIPPOLDT Officer |
9,800 | $1.7M |
| Jun 26, 2026 | DARIN LIPPOLDT Officer |
200 | $33K |
| Jun 5, 2026 | STEPHEN SHERWIN Director |
25,000 | $4.2M |
| Jun 2, 2026 | JULIE COOKE Officer |
36,937 | $5.9M |
| Jun 1, 2026 | JUDE ONYIA Officer |
11,000 | $1.7M |
| May 29, 2026 | INGRID DELAET Officer |
2,261 | $354K |
| May 27, 2026 | JUDE ONYIA Officer |
11,000 | $1.7M |
| May 26, 2026 | DAVID WARREN BOYER Officer |
3,888 | $609K |
| May 19, 2026 | KEVIN CHARLES GORMAN Director |
245,088 | $38.5M |
| May 15, 2026 | RICHARD F POPS Director |
15,000 | $2.4M |
| May 12, 2026 | Norwalk Leslie V Director |
6,310 | $1.0M |
| Jan 16, 2026 | KYLE GANO Officer |
36,400 | $4.9M |
| Dec 15, 2025 | Norwalk Leslie V Director |
11,250 | $1.7M |
| Dec 8, 2025 | DARIN LIPPOLDT Officer |
4,376 | $681K |
| Dec 3, 2025 | GARY A LYONS REVOCABLE LIVING U/A DTD 06/08/2012 Director |
15,000 | $2.3M |
| Nov 28, 2025 | ERIC BENEVICH Officer |
5,970 | $905K |
| Nov 25, 2025 | GEORGE MORROW Director |
15,000 | $2.1M |
Show the other 18 notices
From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.